Month: September 2025

New smartphone license agreement drives projected ARR1 to all-time high of $579 million WILMINGTON, Del., Sept. 22, 2025 (GLOBE NEWSWIRE) — InterDigital, Inc. (Nasdaq: IDCC), a mobile, video and AI technology research and development company, today announced that it has signed a new license agreement with a major Chinese smartphone vendor and has raised its outlook for third quarter 2025. “This new license agreement, which was concluded through amicable negotiation, adds another major smartphone player to our customer base and increases our projected annualized recurring revenue (ARR) by approximately $26 million to a record $579 million,” commented Liren Chen, CEO and President, InterDigital. “Following our $1 billion deal with Samsung, we continue our track record of strong execution across the business and...

REYKJAVIK, ICELAND and LONDON, Sept. 22, 2025 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) has adopted a positive opinion recommending approval for Gobivaz®, Alvotech’s proposed biosimilar to Simponi® (golimumab), a biologic used to treat several chronic inflammatory diseases. “We look forward to working with Advanz Pharma to increase access for patients and healthcare professionals to golimumab, as the reference...

REYKJAVIK, ICELAND and LONDON, UK (September 22, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) has adopted a positive opinion recommending approval for Gobivaz®, Alvotech’s proposed biosimilar to Simponi® (golimumab), a biologic used to treat several chronic inflammatory diseases. “We look forward to working with Advanz Pharma to increase access for patients and healthcare professionals to golimumab, as the reference biologic Simponi®...

C4X Discovery Holdings Ltd C4X Discovery announces selection of a once-daily development candidate from its α4β7 inhibitor programme A potent and selective α4β7 inhibitor with oral bioavailability to support once-daily dosing 22 September 2025 – C4X Discovery Holdings Ltd (“C4XD”), a pioneering Drug Discovery company, today announces the selection of a potential best-in-class pre-clinical candidate from its oral α4β7 integrin inhibitor programme for the treatment of inflammatory bowel disease (IBD). The selected candidate supports once-daily dosing and presents a potentially transformative oral therapy for IBD patients. IBD, which affects more than five million people worldwide1, represents a rapidly growing market projected to reach USD 47.7 billion by 20342. With many patients still underserved by current therapies, C4X...

The share repurchase programme runs as from 26 February 2025 and up to and including 30 January 2026 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 2.25 billion, cf. Corporate Announcement No. 3/2025 of 26 February 2025. The share repurchase programme is initiated and structured in compliance with the EU Commission Regulation No. 596/2014 of 16 April 2014, the so-called “Market Abuse Regulation”, and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”). The following transactions have been made under the program:  Number of shares Average purchase price (DKK) Transaction value (DKK)Accumulated, previous announcement 1,959,088 600.65 1,176,730,31515 September 2025 8,816 701.69 6,186,11916 September...

Enlight Research updated its valuation of INVL Technology, a company that invests in IT businesses which is seeking to divest its portfolio of investments, following the publication of operating results for the first half of 2025.   Analyst Mattias Wallander, who performed the valuation for Enlight Research, increased the target price for INVL Technology’s shares to EUR 4.25 per share, which he said implies a price-to-sales multiple of 0.9x. Enlight’s previous sum-of-the-parts base case fair value target price was EUR 4.12 per share. Before publication of the update report, INVL Technology’s share price on the Nasdaq Vilnius stock exchange was EUR 3.56. “The current net asset value (NAV) discount of 19% is slightly below the long-term average of 22%. In our view, an exit at attractive levels could trigger a decline of the NAV discount...

EIB €250 million to support R&D and industrial investments by Nexans _PRESS RELEASE_The operation is partly backed by an InvestEU guarantee.  The loan will enable Nexans to speed up investments in its research and development programme, as well as in its cable production and copper recycling capacities, optimising the use of raw materials and developing the circular economy. This financing is also part of the EIB’s support for REPowerEU, the programme to strengthen the European Union’s energy autonomy.Paris, September 22, 2025 – The European Investment Bank (EIB) has provided €250 million in financing to Nexans, a global leader in cable system design, manufacturing and associated services. The loan will back Nexans’ research, development and innovation programmes for 2024-2029, together with some industrial investments. These...

LEADING EDGE MATERIALS PROVIDES AN UPDATE ON THE NORR KÄRR HREE PROJECT Vancouver, September 21, 2025 – Leading Edge Materials Corp. (“Leading Edge Materials” or the “Company”) (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) (FRA: 7FL) has through its 100% owned Swedish subsidiary Greenna Mineral AB (“GMAB”) submitted supplementary information in respect of the Company’s application for an Exploitation Concession – 25-year mining lease – for the Norra Kärr Heavy Rare Earth Elements Project (“HREE”). The supplements have been prepared in response to requests by the County Administrative Boards of Jönköping and Östergötland and statements from various regional stakeholders for additional information on the possible environmental impacts of the project. The Company’s response has now been sent to the Mining Inspectorate (Sw. Bergsstaten) for...

Hamilton, Bermuda, September 22, 2025 — Golar LNG Limited (the “Company”) (Nasdaq: GLNG), has mandated a syndicate of banks to arrange a series of fixed income investor meetings commencing Monday, September 22. An offering of USD 144A/Reg S denominated benchmark 5NC2 senior unsecured notes (the “Notes”) may follow, subject to market conditions. Important Information This communication is intended for the sole use of the person to whom it is provided by the sender. This announcement and the offer or sale of the Notes may be restricted by law in certain jurisdictions and therefore persons into whose possession this announcement comes should inform themselves about and observe any such restrictions.  This notice does not constitute or form part of any offer or invitation to sell, or any solicitation of any offer to purchase, the Notes in...